Capitalize on the Industry’s Momentum & Solidify Your Role in Advancing Pulmonary Fibrosis Therapeutics to Patients
The pulmonary fibrosis landscape was undergoing rapid transformation.
With recent clinical breakthroughs reshaping expectations for efficacy and multiple late-stage assets soon to be entering the market, drug developers were operating in a far more complex, competitive, and fast-moving environment. The challenge was no longer simply advancing new therapies, but differentiating them, designing smarter trials, and generating clearer, earlier signals of success.
This shift was driving a growing demand for innovative partners who could help de-risk development and improve decision-making across the pipeline.
The 10th IPF Summit brought together the full ecosystem of IPF and progressive fibrotic ILD drug development, creating a highly focused forum where these challenges were actively addressed.
Across discovery, translational science, and clinical development, attendees sought solutions in predictive disease modeling, biomarker-driven stratification, endpoint optimization, advanced imaging, and efficient clinical trial design.
For solution providers, this was a unique opportunity to be embedded directly in the conversations shaping the next generation of IPF therapeutics.
By engaging with senior decision-makers at the point of strategic need, solution providers could demonstrate how their capabilities directly addressed the field's most pressing challenges.
“Breadth of content covering everything happening in IPF and related diseases. Access to key people and support to make introductions in such a small area.”
Qureight
What You Missed
Unlock High-Value Partnerships
Attendees engaged directly with senior decision-makers actively progressing IPF pipelines. Through curated networking formats, including targeted 1:1 introductions and structured sessions, attendees built meaningful relationships that converted into tangible business opportunities.
Elevate Your Brand With a Highly Targeted Audience
Attendees gained consistent visibility among a concentrated group of IPF leaders and innovators. From pre-event promotion through to on-site engagement, solution providers reinforced their brand as a trusted and credible partner in advancing fibrosis therapeutics.
Differentiate Your Expertise in a Competitive Market
Attendees positioned their capabilities at the forefront of IPF drug development by demonstrating how their solutions solved critical challenges, whether in preclinical models, biomarker strategies, imaging, or clinical execution. Solution providers stood out as strategic partners, not just providers.
Showcase Your Solutions With Real Impact
Attendees brought their offering to life through a dedicated exhibition presence designed to drive interaction and engagement. Solution providers created memorable, hands-on experiences that clearly demonstrated their value and left a lasting impression on prospective partners.
Key Services & Solutions in Need:
Our attendees from respiratory-focused biopharma were looking for service and solution providers with capabilities in the below areas, including but not limited to:
Preclinical Model Providers with Deep Expertise in Recapitulating Human Lung Fibrosis
Providers developed next-generation in vivo and ex vivo platforms that closely emulated the lung microenvironment and disease trajectory to improve translatability from bench to bedside
Advanced Imaging & Diagnostic Tool Developers Supporting Early & Ongoing Disease Insights
Companies offered cutting-edge technologies, from imaging systems to digital screening solutions, that enabled timely diagnosis, tracked disease evolution, and evaluated therapeutic outcomes and efficacy
Comprehensive Biomarker Platform Partners from Discovery to Deployment
Partners offered robust biomarker development, spanning validated, minimally invasive, and exploratory markers, to support patient stratification, disease monitoring, and therapeutic response
Preclinical CROs with Expertise in Fibrosis Mechanisms & Early Target Assessment
Research organizations had strong capabilities in fibrosis biology, supporting target identification, validation, and translational assay development to de-risk discovery efforts
Clinical CROs with Proven Competency in IPF & ILD Trials
Specialist CROs were experienced in navigating rare lung disease trials, offering strategic input on study design, operational support for recruitment and site management, and expertise in meeting regulatory demands
2026 Attending Companies Included
Showcase Your Capabilities
Explore our bespoke sponsorship options include branding, presenting, and exhibiting to build a package tailored to you and your company's goals.
Network With Decision-Makers
Speak with our audience of senior scientific experts during dedicated meeting breaks and structured networking opportunities.
Maintain Your Competitive Edge
Cement your position in a competitive market ensuring your brand is at the heart of biopharma discussions.